Casciaro, Rosaria
 Distribuzione geografica
Continente #
EU - Europa 570
AS - Asia 133
NA - Nord America 74
SA - Sud America 10
AF - Africa 3
OC - Oceania 1
Totale 791
Nazione #
IT - Italia 557
US - Stati Uniti d'America 70
SG - Singapore 52
CN - Cina 38
VN - Vietnam 25
HK - Hong Kong 9
BR - Brasile 8
CA - Canada 3
JP - Giappone 3
AR - Argentina 2
ES - Italia 2
ID - Indonesia 2
IN - India 2
NL - Olanda 2
UA - Ucraina 2
AU - Australia 1
BD - Bangladesh 1
DE - Germania 1
ET - Etiopia 1
FR - Francia 1
GB - Regno Unito 1
IE - Irlanda 1
MA - Marocco 1
MX - Messico 1
NG - Nigeria 1
PL - Polonia 1
RO - Romania 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
Totale 791
Città #
Genoa 398
Vado Ligure 83
Rapallo 41
San Jose 32
Genova 28
Singapore 23
Ho Chi Minh City 10
Hong Kong 9
Beijing 7
Hanoi 5
Milan 3
Tokyo 3
Amsterdam 2
Ashburn 2
Council Bluffs 2
Haiphong 2
Madrid 2
New York 2
Orem 2
Santa Clara 2
Sinnai 2
Addis Ababa 1
Albuquerque 1
Atlanta 1
Banyuwangi 1
Betim 1
Biên Hòa 1
Brandon 1
Brooklyn 1
Caraguatatuba 1
Chehalis 1
Conselheiro Lafaiete 1
Da Nang 1
Dammam 1
Denver 1
Dublin 1
Edison 1
Elizabeth 1
Fes 1
Francisco Beltrão 1
Frankfurt am Main 1
Garibaldi 1
Gobernador Virasoro 1
Hải Dương 1
Itabuna 1
Las Vegas 1
Lauterbourg 1
London 1
Mexico City 1
Milwaukee 1
Mineiros 1
Montreal 1
Newark 1
Ninh Bình 1
Parkland 1
Phúc Yên 1
Ploieşti 1
Roccalumera 1
Rome 1
Shanghai 1
Sousa 1
Sydney 1
Thái Bình 1
Turiisk 1
Tân Tiến 1
Udaipur 1
Virginia Beach 1
Warsaw 1
Totale 707
Nome #
A case of interference in testosterone, DHEA-S and progesterone measurements by second generation immunoassays 143
Mental health and cystic fibrosis: Time to move from secondary prevention to predictive medicine 111
Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method 88
Generation of an induced pluripotent stem cell line (IGGi002A) from nasal cells of a cystic fibrosis patient homozygous for the G542X-CFTR mutation 79
Efficacy of advanced hybrid closed loop systems in cystic fibrosis related diabetes: a pilot study 71
Therapeutic monitoring of Ivacaftor, Tezacaftor and Elexacaftor in patients with cystic fibrosis|Monitoraggio terapeutico di Ivacaftor, Tezacaftor e Elexacaftor in pazienti con fibrosi cistica 70
QUANTIFICATION OF IVACAFTOR, TEZACAFTOR, AND ELEXACAFTOR IN PLASMA OF CYSTIC FIBROSIS PATIENTS BY AN HPLC–MS/MS METHOD 68
Quantification of Ivacaftor, Tezacaftor and Elexacaftor in plasma of cystic fibrosis patients treated with Kaftrio by a validated liquid chromatography-tandem mass spectrometric (LC-MS/MS) method” 63
One-Year Effect of Elexacaftor/Tezacaftor/Ivacaftor Therapy on HbA1c Levels and Insulin Requirement in Patients with Insulin-Dependent Cystic Fibrosis-Related Diabetes: A Retrospective Observational Study 58
A Novel LC-MS/MS Method for the Measurement of Elexacaftor, Tezacaftor and Ivacaftor in Plasma, Dried Plasma Spot (DPS) and Whole Blood in Volumetric Absorptive Microsampling (VAMS) Devices 54
Totale 805
Categoria #
all - tutte 2.830
article - articoli 2.382
book - libri 0
conference - conferenze 448
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.660


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 0 0 0 2 0
2021/202214 0 0 0 0 1 2 0 4 1 3 0 3
2022/202346 2 4 0 5 2 7 0 7 14 0 5 0
2023/202456 1 4 1 5 6 11 7 2 6 3 4 6
2024/2025306 8 22 10 9 15 27 11 68 30 30 39 37
2025/2026367 70 15 26 31 59 18 61 17 38 31 1 0
Totale 805